Turvallisuus- ja tehotutkimus CTX001:n arvioimiseksi potilailla, joilla on vaikea sirppisolutauti
perjantai 21. elokuuta 2026 päivittänyt: Vertex Pharmaceuticals Incorporated
Vaiheen 1/2/3 tutkimus autologisten CRISPR-Cas9-modifioitujen CD34+ ihmisen hematopoieettisten kanta- ja progenitorisolujen (CTX001) kerta-annoksen turvallisuuden ja tehokkuuden arvioimiseksi potilailla, joilla on vaikea sirppisolutauti
Tämä on yksihaarainen, avoin, useaan paikkaan kohdistuva, kerta-annosvaiheen 1/2/3 tutkimus koehenkilöillä, joilla on vaikea sirppisolusairaus (SCD).
Tutkimuksessa arvioidaan autologisten CRISPR-Cas9-modifioitujen CD34+ ihmisen hematopoieettisten kanta- ja progenitorisolujen (hHSPC) turvallisuutta ja tehoa käyttämällä CTX001:tä.
Tutkimuksen yleiskatsaus
Tila
Valmis
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
63
Vaihe
- Vaihe 2
- Vaihe 3
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
-
Brussels, Belgia
- Hopital Universitaire des Enfants Reine Fabiola (HUDERF)
-
-
-
-
-
Rome, Italia
- Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS
-
-
-
-
-
Toronto, Kanada
- The Hospital for Sick Children
-
-
-
-
-
Paris, Ranska
- Hôpital Necker Enfants malades
-
-
-
-
-
Düsseldorf, Saksa
- University Hospital Duesseldorf
-
Regensburg, Saksa
- Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Paediatric Haemotology, Oncology and Stem Cell Transplantation
-
-
-
-
-
London, Yhdistynyt kuningaskunta
- Imperial College Healthcare NHS Trust, Hammersmith Hospital
-
London, Yhdistynyt kuningaskunta
- Royal London and St Bartholomew's Hospital, Pathology and Pharmacy Building
-
-
-
-
California
-
Palo Alto, California, Yhdysvallat, 94304
- Lucile Packard Children's Hospital of Stanford University
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Ann & Robert Lurie Children's Hospital of Chicago
-
Chicago, Illinois, Yhdysvallat, 60612
- University of Illinois at Chicago Hospitals and Health Systems
-
-
New York
-
New York, New York, Yhdysvallat, 10032
- Columbia University Medical Center (21+ years)
-
New York, New York, Yhdysvallat, 10032
- Columbia University Medical Center (≤21 years)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, Yhdysvallat, 38105
- St. Jude Children's Research Hospital
-
Nashville, Tennessee, Yhdysvallat, 37203
- The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
-
-
Texas
-
San Antonio, Texas, Yhdysvallat, 78229
- Methodist Children's Hospital/Texas Transplant Institute
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
12 vuotta - 35 vuotta (Lapsi, Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Tärkeimmät osallistumiskriteerit:
- Vaikean sirppisolusairauden diagnoosi määritellään seuraavasti:
- Dokumentoitu vakavan sirppisolusairauden genotyyppi
- Vähintään kaksi vakavaa vaso-okklusiivista kriisitapahtumaa vuodessa kahden edellisen vuoden ajalta ennen ilmoittautumista
- Kelvollinen autologiseen kantasolusiirtoon tutkijan arvion mukaan
Tärkeimmät poissulkemiskriteerit:
- Saatavilla 10/10 ihmisen leukosyyttiantigeeniä (HLA) vastaava sukulainen luovuttaja
- Aikaisempi hematopoieettinen kantasolusiirto (HSCT)
- Kliinisesti merkittävä ja aktiivinen bakteeri-, virus-, sieni- tai loisinfektio
Muita protokollan määrittämiä sisällyttämis-/poissulkemiskriteerejä voidaan soveltaa
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Exa-cel
Exa-cel (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene).
Participants received a single infusion of exa-cel through a central venous catheter on Day 1.
|
Administered by IV infusion following myeloablative conditioning with busulfan.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
A VOC is a condition of SCD characterized by vaso-occlusion presenting as recurrent pain episodes.
The percentage of participants who remain VOC free after achieving VF12 were data reported in the outcome measure.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Percentage of Participants Who Achieve Neutrophil Engraftment
Aikaikkuna: Up to 24 months post exa-cel infusion.
|
Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, within 42 days after exa-cel infusion without the use of unmodified CD34+ cells after reaching the nadir, defined as ANC <500/µL.
|
Up to 24 months post exa-cel infusion.
|
|
Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment
Aikaikkuna: Up to 24 months post exa-cel infusion.
|
Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, without use of the unmodified CD34+ cells after reaching the nadir, defined as ANC<500/μL.
Time to neutrophil engraftment was calculated by the neutrophil engraftment date subtract exa-cel infusion date +1.
|
Up to 24 months post exa-cel infusion.
|
|
Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment
Aikaikkuna: From Exa-cel infusion up to 2 years after exa-cel infusion
|
Platelet engraftment is defined as the first day of 3 consecutive measurements of unsupported (no platelet transfusions for the last 7 days) platelet ≥50,000/μL on 3 different days after Exa-cel infusion.
For participants discharged early day 7 after the last platelet transfusion will be the day of platelet engraftment, as long as 3 subsequent and consecutive unsupported measurements on 3 different days are >50,000/μL.
For participants who have been discharged prior to platelet engraftment, it is recommended to collect blood every 2 to 3 days to obtain an accurate assessment of platelet engraftment.
Time to platelet engraftment was defined as first of 3 consecutive measurements on 3 different days with platelet ≥50 × 109/L without a platelet transfusion for 7 consecutive days.
|
From Exa-cel infusion up to 2 years after exa-cel infusion
|
|
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Aikaikkuna: From receiving exa-cel infusion up to 2 years
|
From receiving exa-cel infusion up to 2 years
|
|
|
Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion
Aikaikkuna: Within 100 days after exa-cel infusion
|
The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion.
The number and proportion of TRM participants who have died within 100 days, or with at least 100 days post exa-cel infusion.
|
Within 100 days after exa-cel infusion
|
|
Transplant-related Mortality Within 12 Months Post Exa-cel Infusion
Aikaikkuna: Within 12 months post exa-cel infusion
|
The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion.
The number and proportion of TRM within 12 months will be summarized for participants who have died within 12 months, or with at least 12 months post exa-cel infusion.
|
Within 12 months post exa-cel infusion
|
|
All-cause Mortality
Aikaikkuna: From exa-cel infusion up to 2 years
|
All-cause mortality from exa-cel infusion up to 2 years
|
From exa-cel infusion up to 2 years
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage of Participants Free From Inpatient Hospitalization for Severe VOCs Sustained for at Least 12 Months (HF12)
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
The VF12 defines absence of any severe vaso-occlusive crises (VOCs) for at least 12 consecutive months after exa-cel infusion.
Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs were included in the analysis.
Relative reduction from baseline was calculated as 100 % × (Baseline value - post-baseline value) / Baseline value.
Annualized rate is calculated by the Total number of events/number of years.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Percentage of Participants With at Least 90% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
Percentage of participants with at least 90% relative reduction from baseline was reported.
The percentages were calculated relative to the number of participants who did not achieve VF12.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Percentage of Participants With at Least 80% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
Percentage of participants with at least 80% relative reduction from baseline was reported.
The percentages were calculated relative to the number of participants who did not achieve VF12.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Percentage of Participants With at Least 75% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
Percentage of participants with at least 75% relative reduction from baseline was reported.
The percentages were calculated relative to the number of participants who did not achieve VF12.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Percentage of Participants With at Least 50% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
Percentage of participants with at least 50% relative reduction from baseline was reported.
The percentages were calculated relative to the number of participants who did not achieve VF12.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Duration of Severe VOC Free in Participant Who Have Achieved VF12
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
The VF12 means the absence of any severe VOC for at least 12 consecutive months after exa-cel infusion.
The evaluation of the severe VOC free duration in participants who achieved VF12 started 60 days after the last RBC transfusion for post transplant support or SCD management.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Relative Reduction From Baseline in Annualized Rate of Inpatient Hospitalizations for Severe VOCs Up to 24 Months After Exa-cel Infusion
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis. |
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Relative Reduction From Baseline in Annualized Duration of Hospitalization for Severe VOCs Who Did Not Achieve HF12 Up to 24 Months After Exa-cel Infusion
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis. |
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Percentage of Participants With Sustained Fetal Hemoglobin (HbF) Greater Than or Equal to (≥) 20% for at Least 3 Months
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management.
The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Percentage of Participants With Sustained HbF ≥ 20% for at Least 6 Months
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management.
The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Percentage of Participants With Sustained HbF ≥20% for at Least 12 Months
Aikaikkuna: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management.
The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
|
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
|
|
Number of Annualized Red Blood Cells (RBC) Units Transfused After Exa-cel Infusion
Aikaikkuna: 2 years after exa-cel infusion
|
The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.
|
2 years after exa-cel infusion
|
|
Participants With Relative Reduction From Baseline in Number of Annualized Units of Red Blood Cells Transfused
Aikaikkuna: 2 years after exa-cel infusion
|
Relative reduction from baseline = 100% × (Baseline value - post baseline value)/Baseline value.
The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.
|
2 years after exa-cel infusion
|
|
Total Fetal Hemoglobin (HbF) Concentration Over Time
Aikaikkuna: 2 years after exa-cel infusion
|
2 years after exa-cel infusion
|
|
|
Total Hemoglobin (Hb) Concentration Over Time
Aikaikkuna: 2 years after exa-cel infusion
|
2 years after exa-cel infusion
|
|
|
Change From Baseline in Reticulocyte Count Over Time
Aikaikkuna: 2 years after exa-cel infusion
|
2 years after exa-cel infusion
|
|
|
Change From Baseline in Indirect Bilirubin Over Time
Aikaikkuna: 2 years after exa-cel infusion
|
2 years after exa-cel infusion
|
|
|
Percentage of Participants With Detectable Haptoglobin Over Time
Aikaikkuna: 2 years after exa-cel infusion
|
2 years after exa-cel infusion
|
|
|
Percentage of Participants With Lactate Dehydrogenase (LDH) Level <300 Units Per Liter (U/L) Over Time
Aikaikkuna: 2 years after exa-cel infusion
|
2 years after exa-cel infusion
|
|
|
Percentage of Alleles With Intended Genetic Modification Present in Peripheral Blood Leukocytes Over Time
Aikaikkuna: 2 years after exa-cel infusion
|
2 years after exa-cel infusion
|
|
|
Percentage of Alleles With Intended Genetic Modification Present in CD34+ Cells of Bone Marrow Over Time
Aikaikkuna: 2 years after exa-cel infusion
|
2 years after exa-cel infusion
|
|
|
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥12 and <18 Years of Age
Aikaikkuna: 2 years after exa-cel infusion
|
The 11-point pain numerical rating scale (NRS) is used to measures pain intensity on a 1-dimensional score ranging from 0 (no pain) to 10 (worst possible pain).
|
2 years after exa-cel infusion
|
|
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥18 and ≤35 Years of Age
Aikaikkuna: 2 years after exa-cel infusion
|
The 11 point pain numerical rating scale (NRS) is used to measures pain intensity on a 1 dimensional score ranging from 0 (no pain) to 10 (worst possible pain).
|
2 years after exa-cel infusion
|
|
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-Y)Visual Analogue Scale (VAS) for Participants ≥12 and <18 Years of Age
Aikaikkuna: 2 years after exa-cel infusion
|
The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S).
The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.
|
2 years after exa-cel infusion
|
|
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-5L) for Participants ≥18 and ≤35 Years of Age
Aikaikkuna: 2 years after exa-cel infusion
|
The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S).
The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.
|
2 years after exa-cel infusion
|
|
Change in PRO Over Time Assessed Using Functional Assessment of Cancer Therapy-bone Marrow Transplant (FACT-BMT) Score for Participants ≥18 and ≤35 Years of Age
Aikaikkuna: 2 years after exa-cel infusion
|
The Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT) is a quality of life instrument that assesses the effects of bone marrow transplantation (BMT) on a patient's physical, social/family, emotional, and functional well-being while taking into consideration BMT-specific concerns.
The assessment has different questions, each scored on a Likert scale from 0-4.
The overall score is computed by adding scores of the questions and falls in the range 0-148, with higher scores indicating higher levels of overall well-being.
|
2 years after exa-cel infusion
|
|
Change in PRO Over Time Assessed Using Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Score on Different Domains for Participants ≥18 and ≤35 Years of Age
Aikaikkuna: 2 years after exa-cel infusion
|
ASCQ-Me is a disease-specific HRQoL questionnaire for adults with sickle cell disease that assesses Emotional Impact, Pain Impact, Social Functioning Impact, Stiffness Impact, Sleep Impact, Pain Episode Frequency, and Pain Episode Severity.
Domain scores are reported as T-scores standardized to a reference population where mean = 50, and SD = 10.
A change of approximately 5 points (1/2 SD) is considered clinically meaningful.
An increase of 5 points indicates improvement for the impact domains, whereas a decrease of 5 points indicates improvement for the Pain Episode Frequency and Pain Episode Severity domains.
For impact domain items higher score indicates better HRQoL and lower disease burden.
For Pain items lower score indicates a better outcome.
Scores are interpreted relative to the reference population mean of 50, taking into account the direction of scoring for each domain.
|
2 years after exa-cel infusion
|
|
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
Aikaikkuna: 2 years after Exa-cel infusion
|
PedsQL scores were used to assess quality of life of participants.
It is a standardized, generic instrument for measuring health related quality of life (HRQoL) in children and adolescents.
It includes different domains (Psychosocial health, physical functioning, emotional functioning, social functioning, and school functioning).
When completing the PedsQL questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem).
Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.
|
2 years after Exa-cel infusion
|
|
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module (SCD) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
Aikaikkuna: 2 years after exa-cel infusion
|
The PedsQL Sickle Cell Disease Module (PedsQL SCD) is a disease-specific module of the PedsQL.
The tool measures self-reported health-related quality of life in participants with SCD across 9 domains: pain and hurt, pain impact, pain management (mgmt), worry I, worry II, emotions, treatment, communication I, and communication II.
When completing the PedsQL SCD Module questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem).
Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.
|
2 years after exa-cel infusion
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Yhteistyökumppanit
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Yleiset julkaisut
- Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
- Modarai SR, Kanda S, Bloh K, Opdenaker LM, Kmiec EB. Precise and error-prone CRISPR-directed gene editing activity in human CD34+ cells varies widely among patient samples. Gene Ther. 2021 Feb;28(1-2):105-113. doi: 10.1038/s41434-020-00192-z. Epub 2020 Sep 1.
- Brusson M, Miccio A. Genome editing approaches to beta-hemoglobinopathies. Prog Mol Biol Transl Sci. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1.
- Ligon JA, Cupit-Link MC, Yu C, Levine J, Foley T, Rotz S, Sharma A, Gomez-Lobo V, Shah NN. Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance. Transplant Cell Ther. 2024 Aug;30(8):737-749. doi: 10.1016/j.jtct.2024.06.006. Epub 2024 Jun 10.
- Sharma A, Young A, Carroll Y, Darji H, Li Y, Mandrell BN, Nelson MN, Owens CL, Irvine M, Caples M, Jerkins LP, Unguru Y, Hankins JS, Johnson LM. Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers. Pediatr Blood Cancer. 2023 Jun;70(6):e30319. doi: 10.1002/pbc.30319. Epub 2023 Mar 28.
- Persaud Y, Mandrell BN, Sharma A, Carroll Y, Irvine M, Olufadi Y, Kang G, Hijano DR, Rai P, Hankins JS, Johnson LM. Attitudes toward COVID-19 vaccine among pediatric patients with sickle cell disease and their caregivers. Pediatr Blood Cancer. 2023 May;70(5):e30274. doi: 10.1002/pbc.30274. Epub 2023 Mar 1.
- Bhoopalan SV, Yen JS, Levine RM, Sharma A. Editing human hematopoietic stem cells: advances and challenges. Cytotherapy. 2023 Mar;25(3):261-269. doi: 10.1016/j.jcyt.2022.08.003. Epub 2022 Sep 17.
- Sharma A, Locatelli F, Bhatia M, Molinari L, Mapara MY, Liem RI, Dedeken L, Wall D, Eckrich MJ, Kuo KHM, Smith W, Imren S, Kohli P, Li N, Liu T, Rubin J, Hobbs W, Grupp SA, Frangoul H. Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel. Blood Adv. 2025 Dec 23;9(24):6481-6490. doi: 10.1182/bloodadvances.2025016701.
- Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem RI, Telfer P, Shah AJ, Cavazzana M, Corbacioglu S, Rondelli D, Meisel R, Dedeken L, Lobitz S, de Montalembert M, Steinberg MH, Walters MC, Eckrich MJ, Imren S, Bower L, Simard C, Zhou W, Xuan F, Morrow PK, Hobbs WE, Grupp SA; CLIMB SCD-121 Study Group. Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024 May 9;390(18):1649-1662. doi: 10.1056/NEJMoa2309676. Epub 2024 Apr 24.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Tiistai 27. marraskuuta 2018
Ensisijainen valmistuminen (Todellinen)
Maanantai 7. heinäkuuta 2025
Opintojen valmistuminen (Todellinen)
Maanantai 7. heinäkuuta 2025
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Perjantai 9. marraskuuta 2018
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 15. marraskuuta 2018
Ensimmäinen Lähetetty (Todellinen)
Maanantai 19. marraskuuta 2018
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 16. syyskuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Perjantai 21. elokuuta 2026
Viimeksi vahvistettu
Lauantai 1. elokuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- CTX001-121
- 2024-516067-83-00 (Ctis)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Joo
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Yhdysvalloissa valmistettu ja sieltä viety tuote
Joo
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .